Wuxi International Life Science Innovation Park Reappears at CIIE, Driving Global Healthcare Integration and Innovation
The highly anticipated China International Import Expo (hereinafter referred to as the “CIIE”) has entered its third day. Today, the Wuxi International Life Science Innovation Park, jointly established by the Wuxi Municipal People’s Government and Wuxi High-Tech Zone in partnership with AstraZeneca and making another appearance at the CIIE, announced the introduction of 12 innovative enterprises from both domestic and overseas markets. In addition to facilitating two innovation collaborations with companies within the park, the event also featured several important unveiling ceremonies and signing events.
Hui Jianlin, Vice Governor of Jiangsu Province; Helena Sångeland, Swedish Ambassador to China; Huang Lan, Deputy Secretary-General of the Jiangsu Provincial People’s Government; Zhao Jianjun, Director of the Jiangsu Provincial Department of Commerce; Fei Shaoyun, Director of the Foreign Affairs Office of the Jiangsu Provincial People’s Government; Yin Jianqing, President of the Jiangsu Council for the Promotion of International Trade; heads of other relevant provincial departments; Jiang Min, Vice Mayor of Wuxi, Secretary of the Party Working Committee of Wuxi High-tech Zone, and Secretary of the Xinwu District Party Committee; Zhou Changqing, Vice Mayor of Wuxi; heads of relevant departments in Wuxi City and the High-tech Zone; Wang Lei, Global Executive Vice President of AstraZeneca, President of International Business and China; Lai Minglong, General Manager of AstraZeneca China; Xu Jing, Vice President of AstraZeneca China and Head of Digitalization and Commercial Innovation; Huang Bin, Vice President of AstraZeneca China and Head of Corporate Affairs and Market Access; along with representatives from the signing enterprises, jointly attended the event.
Jiangsu Provincial Vice Governor Hui Jianlin Visits the Wuxi International Life Science Innovation Park at the AstraZeneca Booth
Leveraging the Innovation Park’s resource integration capabilities and platform advantages, Sweden’s BioVentureHub also entered into a China-Sweden strategic cooperation agreement for medical innovation with the Innovation Park at this year’s CIIE, further expanding international collaboration and pooling global innovative strength.
Ibrahim Baylan, Sweden’s Minister for Enterprise and Innovation, delivered a specially recorded video address at the online signing ceremony for the China-Sweden Strategic Cooperation on Medical Innovation, expressing his expectations and support for building an international collaborative ecosystem.
Meanwhile, the Wuxi Municipal Government, in collaboration with AstraZeneca, Tigermed, and CICC, jointly announced the “Wuxi International Health Investment and Innovation Conference” initiative, aiming to accelerate the enhancement of Wuxi’s global influence in the biopharmaceutical industry.
With the strong support of the Wuxi Municipal Government and the High-Tech Zone Government, the Wuxi International Life Science Innovation Park, announced its opening in September 2019, officially commenced operations this April. Despite challenges posed by the pandemic, the Innovation Park has maintained uninterrupted domestic and international exchanges, actively introduced innovative forces, and empowered enterprise development through multi-dimensional initiatives, yielding fruitful results.
Despite the significant challenges posed by the pandemic, I·Campus welcomed 12 innovative enterprises from both domestic and international markets. These new tenants span multiple fields, including gene sequencing, Internet Plus, artificial intelligence, wearable devices, and surgical navigation, continuously expanding the boundaries of the park’s innovative development.
Leveraging its resource integration capabilities and platform advantages, and with the Wuxi Municipal Government and High-Tech Zone Government continuously providing policy support and comprehensive safeguards for the development of resident enterprises, the Innovation Park collaborates closely with its tenant companies to deeply empower the integration and development of the innovative ecosystem and industry.
Guanhe Pharma, a company within the park, and AstraZeneca jointly signed a collaboration agreement for the co-development and commercialization of companion diagnostics.
Wuxi Municipal Healthcare Security Administration and Wuxi High-Tech Zone Sign Strategic Framework Agreement to Establish “New District Workstation of Wuxi Pharmaceutical Procurement and Bidding Center” in the Innovation Park, Aiming to Secure Greater Policy Support and Resource Guarantees for the Incubation of Innovative Drugs, Medical Devices, and Healthcare Solutions within the Park.
“I·Campus Foreign Affairs Service Station” was officially unveiled, establishing a “green channel” for talent acquisition and foreign affairs services within the park. This initiative aims to support the Innovation Park in building an international community, enhancing its level of internationalization, and further attracting overseas innovation projects.
“CCHRPP Wuxi Medical Research Certification Center” was simultaneously unveiled, providing further support for improving the medical innovation ecosystem within the park, from scientific research to industrialization.
“Wuxi European Life Science Innovation Industrial Park” was also unveiled on the same day, further expanding international cooperation and gathering global innovation forces.
“The Wuxi Biopharmaceutical Industry Association and the CEIBS Alumni Healthcare Industry Association” also signed agreements to establish their presence in the park, jointly promoting the integrated development of the industry.
Building on AstraZeneca’s innovative iClinic Future Clinic project, Dianfu and Shenzhi, enterprises based in the Wuxi and Hangzhou Innovation Parks, also signed agreements at the China International Import Expo (CIIE) to launch innovative collaborations. Over the next year, they will carry out disease screening for one million people at the primary care level.
Over the past year since its opening, multiple companies have achieved significant milestones: Qiyi Medical joined the park at the beginning of the year and became a partner in AstraZeneca’s “End-to-End Management of Chronic Respiratory Airway Diseases” project, facilitating the widespread deployment of all-in-one respiratory risk screening devices in over 470 hospitals and securing investment from a top-tier U.S. dollar fund. The Innovation Park has also encouraged tenant companies to explore deeper collaborations with more cross-industry partners; for instance, Shannmi, a tumor genetic testing company, partnered with Tencent in July to jointly develop the MiGuang Online Tumor Multidisciplinary Team (MDT) Platform. At the AstraZeneca booth during the China International Import Expo (CIIE), numerous companies—including Guanhe, Jinse, LinkDoc, Liangzhun, Omron, Qiyi, Shannmi, UST, Xin’an Medical, and Xincheng Magnesium—showcased their latest innovative achievements incubated in forward-looking fields.
Since its opening in 2019, the Wuxi International Life Science Innovation Park has successfully attracted nearly 30 outstanding domestic and overseas enterprises and seven international strategic partners. Commenting on the company’s presence at this year’s China International Import Expo (CIIE), Lei Wang, Global Executive Vice President of AstraZeneca and President of International Business and China, stated, “The CIIE provides an excellent window for promoting two-way communication and cooperation in innovation between domestic and overseas markets. The achievements made by the Innovation Park in its first year would not have been possible without the joint support from government, industry, academia, research institutions, and healthcare providers. AstraZeneca will remain committed to its mission, continuing to leverage our advantageous resources and industry expertise. We look forward to working with more partners to build an open, collaborative, and win-win global medical innovation ecosystem. In achieving our own development, we aim to bolster China’s medical innovation capabilities, thereby benefiting patients in China and around the world.”
Wuxi International Life Science Innovation Park (I·Campus) is a life science innovation incubation platform jointly established by the Wuxi Municipal Government, Wuxi High-Tech Zone, and AstraZeneca, a global biopharmaceutical company. It was first announced at the Boao Forum for Asia in March 2019. The core R&D area of the park covers approximately 300,000 square meters. By building an open innovation ecosystem, Wuxi International Life Science Innovation Park will provide domestic and overseas innovative enterprises with a one-stop innovation empowerment platform for project implementation, innovation incubation, commercial acceleration, and scaling up. With multi-party support from government, industry, academia, research institutions, healthcare providers, and investors, Wuxi International Life Science Innovation Park is committed to becoming the preferred park for domestic and overseas life science innovators to deeply cultivate the Chinese market and connect with the global market, gathering global wisdom, contributing to Healthy China, and embarking on international aspirations.
WeChat ID:ICampus-Wuxi
Official Website:www.icampuswuxi.com
Contact Number:+86-510-81999975
Contact Email:icampus@astrazeneca.com